NCT00443976View on ClinicalTrials.gov

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 30, 2007

Primary Completion Date

April 9, 2010

Study Completion Date

January 6, 2012

Conditions
Non-Hodgkins LymphomaUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Aurora kinase inhibitor AT9283

The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.

Trial Locations (2)

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

NCIC Clinical Trials Group

NETWORK